Day One Biopharmaceuticals insider trading

Bought

—

Sold

$423K

none on a 10b5-1 plan

Net

−$423K

Insiders

5

• Merendino Lauren

  Chief Commercial Officer

  −$67.4K

  Feb 17, 2026

  5,814 sh · $11.60

• Dubow Adam

  Gen Counsel & Secretary

  −$74.2K

  Feb 17, 2026

  6,395 sh · $11.60

• York Charles N II

  COO and CFO

  −$70.4K

  Feb 17, 2026

  6,065 sh · $11.60

• Bender Jeremy

  Chief Executive Officer · Director

  −$179.3K

  Feb 17, 2026

  15,459 sh · $11.60

• Vasconcelles Michael

  Head of Research and Dev.

  −$31.6K

  Feb 17, 2026

  2,728 sh · $11.60

Largest sale

−$426.6K of DAWN by Blackman Samuel C. (Head Of R&D) on Sep 10, 2024, under a 10b5-1 plan.

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

SEC industry classification

Pharmaceutical Preparations

Headquarters

Brisbane, CA

Incorporated in

DE

SEC Central Index Key

0001845337

Previously filed as

Day One Biopharmaceuticals Holding Co LLC

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

Open-market purchase (code P)

An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.

Grants and option exercises (codes A, M)

Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.

Cluster buy

Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Are DAWN insiders buying or selling?

Between Feb 17, 2026 and Feb 17, 2026, 5 Day One Biopharmaceuticals insiders made no open-market purchases and 5 sales worth $423K, a net sale of $423K.

How much DAWN stock have insiders bought and sold in the last two years?

Between Jul 01, 2024 and Jun 30, 2026, 6 Day One Biopharmaceuticals insiders made no open-market purchases and 35 sales worth $3.6M. 7 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 13 sales ($864K). The largest sale was Blackman Samuel C. selling $426.6K on Sep 10, 2024.

What was the largest recent DAWN insider trade?

Bender Jeremy (Chief Executive Officer · Director) sold $179.3K of DAWN stock on Feb 17, 2026 at about $11.60 a share.

When did an insider last buy DAWN shares?

No open-market purchase by a Day One Biopharmaceuticals insider appears in the filings from Feb 17, 2026 to Feb 17, 2026 — every recorded open-market transaction in that period was a sale.

Where does DAWN insider trading data come from?

From the Form 4 filings Day One Biopharmaceuticals's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.